164 related articles for article (PubMed ID: 12648786)
1. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
Sanguineti G; Marcenaro M; Franzone P; Foppiano F; Vitale V
Radiother Oncol; 2003 Feb; 66(2):151-7. PubMed ID: 12648786
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
3. The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.
Onal C; Topkan E; Efe E; Yavuz M; Arslan G; Yavuz A
Br J Radiol; 2009 Dec; 82(984):1019-26. PubMed ID: 19581310
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy.
Zelefsky MJ; Harrison A
Urology; 1997 Mar; 49(3A Suppl):38-45. PubMed ID: 9123735
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?
Zapatero A; Ríos P; Marín A; Mínguez R; García-Vicente F
Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):600-7. PubMed ID: 17051950
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
[TBL] [Abstract][Full Text] [Related]
7. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.
Sanguineti G; Agostinelli S; Foppiano F; Franzone P; Garelli S; Marcenaro M; Orsatti M; Vitale V
Br J Cancer; 2002 Jun; 86(12):1843-7. PubMed ID: 12085173
[TBL] [Abstract][Full Text] [Related]
9. Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.
Samper PM; López Carrizosa MC; Pérez Casas A; Vallejo C; Rubio Rodríguez MC; Pérez Vara C; Melchor Iñiguez M
Clin Transl Oncol; 2006 Aug; 8(8):599-605. PubMed ID: 16952849
[TBL] [Abstract][Full Text] [Related]
10. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose.
Lilleby W; Dale E; Olsen DR; Gude U; Fosså SD
Acta Oncol; 2003; 42(1):10-4. PubMed ID: 12665325
[TBL] [Abstract][Full Text] [Related]
11. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
12. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer.
Stasi M; Munoz F; Fiorino C; Pasquino M; Baiotto B; Marini P; Malinverni G; Valdagni R; Gabriele P
Radiother Oncol; 2006 Sep; 80(3):363-70. PubMed ID: 16959344
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy.
Zelefsky MJ; Leibel SA; Burman CM; Kutcher GJ; Harrison A; Happersett L; Fuks Z
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):755-61. PubMed ID: 8040021
[TBL] [Abstract][Full Text] [Related]
14. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
Yang FE; Chen GT; Ray P; Vaida F; Chiru P; Hamilton RJ; Spelbring D; Abellera M; Vijayakumar S
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1009-17. PubMed ID: 7493827
[TBL] [Abstract][Full Text] [Related]
15. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.
Jackson A; Skwarchuk MW; Zelefsky MJ; Cowen DM; Venkatraman ES; Levegrun S; Burman CM; Kutcher GJ; Fuks Z; Liebel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):685-98. PubMed ID: 11172950
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study.
Ikeda I; Mizowaki T; Norihisa Y; Takayama K; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O; Hiraoka M
Jpn J Clin Oncol; 2014 Feb; 44(2):180-5. PubMed ID: 24379210
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
19. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
20. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
